- Interval Changes in PSMA PET/CT During Radium‑223 Therapy for Metastatic Bone Disease from Castration‑Resistant Prostate Cancer
-
Probst S, Bjartell A, Anand A, Skamene T, Ferrario C
- KMID: 2532369
- Nucl Med Mol Imaging.
- 2022 Aug;56(4):188-195.
- doi: 10.1007/s13139-022-00754-6
Background Radium-223, an alpha-emitting therapeutic radiopharmaceutical, prolongs overall survival (OS) in patients with symptomatic bone-predominant metastatic castration-resistant prostate cancer (mCRPC). PSMA PET/CT is a molecular imaging tool for whole-body imaging... -
- CITED
-
- Close
- SHARE
-
- Close
